/
Vasopressors Jennifer & Joshua Chalk Talk Vasopressors Jennifer & Joshua Chalk Talk

Vasopressors Jennifer & Joshua Chalk Talk - PowerPoint Presentation

danika-pritchard
danika-pritchard . @danika-pritchard
Follow
377 views
Uploaded On 2018-03-14

Vasopressors Jennifer & Joshua Chalk Talk - PPT Presentation

1172014 Go Hawks Vasopressors What When Why Wprecautions Vasopressors Definitions Pressor Increases blood pressure by stimulating constriction of blood vessels Increases vascular tone ID: 650205

patients shock vasopressin drip shock patients drip vasopressin norepinephrine vasopressors blood mortality septic central peripheral dopamine pharmacy decrease access

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Vasopressors Jennifer & Joshua Chalk..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Vasopressors

Jennifer & Joshua Chalk Talk

1/17/2014

Go Hawks!Slide2

Vasopressors

What?

When?

Why?

Wprecautions?Slide3

VasopressorsSlide4

Definitions

Pressor: Increases blood pressure by stimulating constriction of blood vessels

Increases vascular toneSlide5

Definitions

Inotrope: Alters force or energy of muscular contractions

Positive: Increases myocardial contractilitySlide6

Definitions

Shock: Inability of oxygen delivery to meet tissue oxygen requirements

Hypovolemia (decreased circulating volume)

Cardiac function impairment (decreased myocardial contractility)

Inappropriate distribution of cardiac output secondary to abnormal vasodilatationSlide7
Slide8

Pathophysiology

Cardiac output

Heart Rate

Sympathetic and Parasympathetic tone

Circulating chatecolamines

Preload

Changes in venous return

Changes in plasma volume

Contractility

Sympathetic tone

Circulating catecholaminesSlide9

Progression to Late ShockSlide10

Septic Shock

Hypotension despite adequate fluid resuscitation

Presence of hypoperfusion or organ dysfunction

Acidosis / alteration in mental status

Sepsis: temp >38°C or <36°C; HR> 90 bpm*

respiratory rate>20 breaths/min, need for mechanical ventilation; WBC 12,000*Slide11

Hemorrhagic Shock

Rapid reduction in blood volume

Heart rate and blood pressure responses can be variable

Vasopressors may be harmful if pt is hypovolemic; Despite improvement in blood pressure, renal blood flow decreases and renal vascular resistance risesSlide12

Cardiogenic Shock

Pump failure

Results when more than 40% of myocardium damaged

Similar circulatory and metabolic changes to hemorrhagic shockSlide13

Treatment

Fluids / Procedures

DRUGS!

Vasopressors

InotropesSlide14

Fluid Requirements

“There is no evidence-based support for one fluid-type over another”(surviving sepsis)

Early fluid administration more important than fluid type

HES/Albumin/Gelatin/LR; Rivers et alSlide15

PharmacologySlide16

Pharmacology

Adrenergic System

Alpha adrenergic

Increases vascular tone

May decrease cardiac output

May decrease regional blood flow (renal, spleen, cutaneous)

Beta adrenergic

Maintains blood flow

May increase cellular metabolism

May decrease immune systemSlide17

Pharmacology

Dopaminergic

Increases splanchnic and renal perfusion

Facilitates resolution of lung edema

Associated with harmful immunological effects

May decrease prolactin, human growth hormoneSlide18

Vasopressors

Norepinephrine

Dopamine

Epinephrine

Vasopressin

PhenylephrineSlide19

Vasopressors

PhenylephrineSlide20

VasopressorsSlide21

Vasopressors

VasopressinSlide22

ReceptorsSlide23

ReceptorsSlide24

Norepinephrine

Historically considered a poor choice in shock due to excessive vasoconstriction and end-organ hypoperfusion

This opinion began to change recently

Benefits: raise arterial pressure and systemic vascular resistance

Maintain cardiac function / improve renal functionSlide25

Dopamine

More potential for arrhythmias/increased heart rate

May increase both blood pressures and flow; may be best used in patient with low heart rate and inadequate fluid resuscitationSlide26

Epinephrine

Epi often used as 3

rd

line after NE and DA failed

Epi always first line in Anaphylactic ShockSlide27

Vasopressin

Vasopressin works on V1,V2,V3 receptors

Increases bp / may improve mortality

May decrease NE requirements

May improve renal function

Avoid in MI; in cardiac ischemia may decrease contractility/lower CO/increase mortality

At doses > 0.04 units/hr may decrease GI blood flowSlide28

Studies

VASST

Vasopressin (0.03 un/hr) v. NE in septic shock

No significant difference in mortality at 28 days

Decreased mortality in patients with less severe septic shock (lowest quartile of arterial lactate)

Vaso + corticosteroids decreased mortality v. NE + corticosteroids

Conclusion: May be effective in patients with less severe septic shock already receiving NESlide29

Studies

Martin: Norepi in Septic Shock

97 patients in septic shock

Dopamine started at 5mcg/kg/min, titrated to 15mcg/kg/min

If hypotension persisted:

DA increased to 25mcg/kg/min OR

NE added at 0.5mcg/kg/minSlide30

Martin et al

Patients receiving NE had best survival rate on all days of hospital stay (p<0.001)

Mortality strongly associated with high lactate and low urine output

“NE was associated with a highly significant decrease in hospital mortality. The data contradict the notion that norepinephrine potentiates end organ hypoperfusion through excessive vasoconstrictionSlide31

Studies

De Backer: Norepi v Dopamine in Shock.

Multicenter study, 1679 patients

DA with 52.5% mortality

NE with 48.5% mortality (p=0.10)

More arrhythmic events with DA (207v102)Slide32

DeBacker et al

Included Septic (62.2%), Cardiogenic (16.7%), and Hypovolemic (15.7%) shock.

More patients in DA group required 2

nd

pressor

Subgroup: DA in cardiogenic shock increased mortality significantly (p=0.03)

Conclusion: “This study raised serious concern about the safety of Dopamine”Slide33

Practical Considerations

Vascular Access

Access to drug

Compatibilities

Titration

Adverse effectsSlide34

Central vs. Peripheral line

Central always preferred

Peripheral

Line

Must flush well

As big as possible

Preferred infusion site = forearm (basilic, cephalic, and median antebrachial)

Caution with dorsum of hand, wrist, feet

Decision: life vs. limb

MD must be aware

Guardrails alert: pressor must go through central line

Override with MD approval documented

Slower titration with obese patientsSlide35

Central vs. Peripheral line

Jean-Damien, R et al. Central or peripheral catheters for initial venous access of ICU patients

Patients randomized: peripheral (N=128) or central access (N=135)

Included epinephrine/norepinephrine doses up ~0.4 mcg/kg/min (for 75 kg patient); Dopamine/dobutamine doses up to 10 mcg/kg/min

Less major complications with central rather than peripheral access (0.64 vs. 1.04, p<0.02)

Majority of complications in PIV group were inability to insert PIV

Subcutaneous diffusion (aka extravasation)

More with peripheral rather than central access

19/128 (~15%) vs. 2/135 (~1.5%)

Average length of stay ~12 days

All patients managed with “observation and conservative management”

http://emcrit.org/podcasts/peripheral-vasopressors-extravasation/

Ricard JD, et al. Central or peripheral catheters for initial venous access of ICU patients: a randomized controlled trial. Crit Care Med. 2013 Sep;41(9):2108-15Slide36

Extravasation

Drug

Effect

Mechanism(s) of tissue injury

Dobutamine

Irritant; Rare reports of vesicant effects

Cytotoxicity, acidic pH

Dopamine, Epinephrine, Phenylephrine Norepinephrine, Vasopressin

Vesicants

Vasoconstriction Slide37

Extravasation

Phentolamine

Short-term alpha-adrenergic blocking activity

Administration

vasodilatation of vascular smooth muscle

Administer ASAP

Infiltrate area of extravasation with phentolamine: 5 mg diluted in 9 mL NS

Should see near immediate effects; otherwise consider additional dose (Max = 10 mg)Slide38

Getting a Drip Up and On

Sequence of events

Hypotensive patient

Recognize pressor needed

Physician orders

Order recognized in ORCA

Pharmacy technician makes drip

Pharmacist checks drip

Pharmacy technician tubes drip

Nurse collects from tube station

Nurse starts dripSlide39

Getting a Drip Up and On

Dopamine, Dobutamine

Premixed and in PYXIS!

Epinephrine, Phenylephrine, Norepinephrine, Vasopressin

Mixed by technician after order received in inpatient pharmacySlide40

Getting a Drip Up and On

Persistent hypotension

→ Ask MD if drip should be sent to bedside

Cost to hospital per bag: $1.56 – 7.23

Call pharmacy

Ask for pharmacist STAT (state you are calling from ED)

State patient scenario briefly

Request pharmacy to start making drip

ONLY Physician may give verbal order with U#, drug and dose

Otherwise MD must place order in ORCA before drip is sent

Request pharmacy to notify PSS when drip sentSlide41

Compatibilities

Variable –

Call pharmacy

Most likely to be compatible: Epinephrine, dobutamine, dopamine, vasopressin

Maybe: Phenylephrine

Generally not tested: Norepinephrine Slide42

Titration

Starting a drip

MD must order

Generally best to start low and increase

Adverse effects frequently dose related

Switching a patient from OSH

Check patient weight and dosing UNITS

If the same, transition to UW pump and drug

If different:

Call pharmacy to convert

Start in the low to mid range of dosing and titrateSlide43

Adverse Reactions

Epinephrine

Norepinephrine

Dopamine

Dobutamine

Vasopressin

Phenylephrine

Tachycardia

x

High doses

x

Arrhythmias

x

High doses

x

x (ventricular)

Increased myocardial O2 demand

x

x

x

Decreased perfusion to vital organs

x

x

x (less)

x

Nausea/vomiting

x

x

Metabolic acidosis

x

x

Hypersensitivity

x (contains sulfites)

Extravasation

x

x

x

x

x

xSlide44

References

De Backer D et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-89.

Martin C et al. Effect of norepinephrine on the outcome of shock. Crit Care Med 2000; 28:2758 –2765

Perel A. The initial hemodynamic resuscitation of the septic patient according to Surviving Sepsis Campaign guidelines – does one size fit all? Critical Care 2008, 12:223

Russel J. Vasopressin in the management of septic shock. Critical Care 2011, 15:226

Russell JA, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358:877-887.

Ricard JD, et al. Central or peripheral catheters for initial venous access of ICU patients: a randomized controlled trial. Crit Care Med. 2013 Sep;41(9):2108-15